Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
L-DOPA sensitizes vasomotor tone by modulating the vascular alpha1-adrenergic receptor
Daiki Masukawa, Motokazu Koga, Anna Sezaki, Yuka Nakao, Yuji Kamikubo, Tatsuo Hashimoto, Yuki Okuyama-Oki, Aderemi Caleb Aladeokin, Fumio Nakamura, Utako Yokoyama, Hiromichi Wakui, Hiroshi Ichinose, Takashi Sakurai, Satoshi Umemura, Koichi Tamura, Yoshihiro Ishikawa, Yoshio Goshima
Daiki Masukawa, Motokazu Koga, Anna Sezaki, Yuka Nakao, Yuji Kamikubo, Tatsuo Hashimoto, Yuki Okuyama-Oki, Aderemi Caleb Aladeokin, Fumio Nakamura, Utako Yokoyama, Hiromichi Wakui, Hiroshi Ichinose, Takashi Sakurai, Satoshi Umemura, Koichi Tamura, Yoshihiro Ishikawa, Yoshio Goshima
View: Text | PDF
Research Article Cell biology Vascular biology

L-DOPA sensitizes vasomotor tone by modulating the vascular alpha1-adrenergic receptor

  • Text
  • PDF
Abstract

Blood pressure is regulated by extrinsic factors including noradrenaline, the sympathetic neurotransmitter that controls cardiovascular functions through adrenergic receptors. However, the fine-tuning system of noradrenaline signaling is relatively unknown. We here show that l-3,4-dihydroxyphenylalanine (L-DOPA), a precursor of catecholamines, sensitizes the vascular adrenergic receptor alpha1 (ADRA1) through activation of L-DOPA receptor GPR143. In WT mice, intravenous infusion of the ADRA1 agonist phenylephrine induced a transient elevation of blood pressure. This response was attenuated in Gpr143 gene–deficient (Gpr143–/y) mice. Specific knockout of Gpr143 in vascular smooth muscle cells (VSMCs) also showed a similar phenotype, indicating that L-DOPA directly modulates ADRA1 signaling in the VSMCs. L-DOPA at nanomolar concentrations alone produced no effect on the VSMCs, but it enhanced phenylephrine-induced vasoconstriction and intracellular Ca2+ responses. Phenylephrine also augmented the phosphorylation of extracellular signal–regulated kinases in cultured VSMCs from WT but not Gpr143–/y mice. In WT mice, blood pressure increased during the transition from light-rest to dark-active phases. This elevation was not observed in Gpr143–/y mice. Taken together, our findings provide evidence for L-DOPA/GPR143 signaling that exerts precursor control of sympathetic neurotransmission through sensitizing vascular ADRA1.

Authors

Daiki Masukawa, Motokazu Koga, Anna Sezaki, Yuka Nakao, Yuji Kamikubo, Tatsuo Hashimoto, Yuki Okuyama-Oki, Aderemi Caleb Aladeokin, Fumio Nakamura, Utako Yokoyama, Hiromichi Wakui, Hiroshi Ichinose, Takashi Sakurai, Satoshi Umemura, Koichi Tamura, Yoshihiro Ishikawa, Yoshio Goshima

×

Figure 5

Interaction between GPR143 and ADRA1B.

Options: View larger image (or click on image) Download as PowerPoint
Interaction between GPR143 and ADRA1B.
(A) Co-immunoprecipitation (Co-IP...
(A) Co-immunoprecipitation (Co-IP) of ADRA1B-Myc and GPR143-HA. Bands were detected by anti-Myc (left) or by anti-HA (right) antibodies. (B) Protein levels of pERK and whole ERK 10 minutes after the treatment with phenylephrine. (C) Summarized data of pERK/ERK (% of control) in HEK293 cells coexpressing ADRA1B-Myc and free-EGFP or ADRA1B-Myc and GPR143-EGFP (F1,32 = 7.899, P < 0.001, n = 5). (D) Interaction between ADRA1B-Myc and GPR143-HA in the presence or absence of L-DOPA. Note that the interaction was enhanced in the presence of L-DOPA for 1 minute. The arrowhead indicates predicted ADRA1B. (E) TIRF microscopic images of GPR143-EGFP (left), ADRA1B-mCherry (center), and merged images (right) as indicated by white arrowheads (n = 3, independent experiments). Scale bar: 3.5 μm. (F) FRET efficiency between Venus and CFP at the plasma membrane. *P < 0.05, **P < 0.01, 1-way ANOVA with Bonferroni’s multiple comparisons test (n = 36–59). n.s., not significant. (G) Displacement binding curve of [H3]-prazosin (0.4 nM) by phenylephrine in HEK293 cells expressing ADRA1B-Myc and GPR143-EGFP or ADRA1B-Myc and free-EGFP (F1,40 = 19.31, ***P < 0.001, n = 3). Two-way ANOVA with Bonferroni’s multiple comparisons test.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts